CureVac’s COVID-19 Vaccine Produces Grade 3 Adverse Events
Biopharmaceutical company CureVac NV of Tübingen, Germany has released the interim results of its Phase 1 clinical trial on its experimental CVnCoV vaccine COVID-19. The vaccine, which was given to more than 250 healthy adults 18 to 60 years of age, is based on messenger ribonucleic acid (mRNA) technology.1 2 Unlike traditional vaccines, mRNA vaccines […]
Healthy Clinical Trial Subjects Suffer Grade 3 Side Effects to Moderna’s mRNA COVID-19 Vaccine
On May 18, 2020, Moderna, Inc. of Cambridge, Massachusetts announced that it had obtained “positive interim clinical data” from a Phase 1 human clinical trial of its experimental mRNA-1273 COVID-19 vaccine that began on Mar. 16. The biotechnology company said that eight of the 45 healthy adult volunteer trial subjects developed antibodies that may provide […]
